RealTime Dynamix™: Humira in Immunology US Q1 2017 Spotlight

Is AbbVie “Immune” to the Threats?

Despite an onslaught of new mechanism drugs introduced in the leading autoimmune and inflammatory conditions over the past year, AbbVie’s Humira holds strong!

Spherix Global Insights RealTime Dynamix reports in Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Crohn’s and Ulcerative Colitis and Atopic Dermatitis cover the market dynamics that impact Humira in the brand’s key indications. How is this well established brand doing and how does the performance differ across the specialties?

Click the button below to download highlights from these reports.

Download Humira in Immunology Spotlight